Efficacy of hybrid blood purification for SA-AKI subtypes identified by CCL14: study protocol for a single-centre randomized controlled clinical trial.

ABSTRACT: Sepsis-associated acute kidney injury (SA-AKI) is a commonly encountered complex heterogeneous syndrome in critically ill patients with sepsis. Under the interaction of genotype and pathogenic factors, SA-AKI can lead to various clinical phenotypes and subphenotypes, and this heterogeneity complicates the assessment of the efficacy of treatment measures for sepsis in clinical trials. Early identification of SA-AKI high-risk patients with specific subphenotypes and timely implementation of supportive treatments may improve adverse outcomes for these patients. High levels of C-C motif chemokine ligand 14 (CCL14) serve as a biomarker that can early identify critically ill patients with persistent SA-AKI. However, the effects of different supportive treatment strategies on the prognosis of SA-

SUBMITTER: Shi K 

PROVIDER: S-EPMC12382114 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature